Seth Klarman portfolio · Q2 2018
The Baupost Group, L.L.C. · CIK 0001061768 ·13F filings on SEC EDGAR
In Q2 2018, The Baupost Group, L.L.C. reported 33 positions worth $11.4B. Its largest holding was 90130A101 at 17.1% of the portfolio, and the top 10 made up 77%. Its largest new position was 19626G108 ($310M), and it sold out of TWX.
- NEW 6
- ADD 9
- REDUCE 1
- EXIT 6
Portfolio map
Each box is a position sized by its value. Color shows the change in shares from the previous quarter.
Portfolio history
Q2 2013 to Q2 2018, 21 quarters
Weight of the largest holdings
The 7 holdings with the highest weight in any quarter shown, stacked with all others to 100%.
Holding timeline
Shade shows the weight in each quarter. A blank cell means the holding was not reported that quarter.
Holdings
Click a holding to see its price chart with the quarters the investor bought or sold.
| Name | Weight | Avg. cost (est.) | Latest price | Gain/loss | Value |
|---|---|---|---|---|---|
90130A101 TWENTY FIRST CENTY FOX INC | 17.12% | $35.93 | $48.12 | +33.9% | $1.9B |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SYF SYNCHRONY FINANCIAL | 8.55% | $29.47 | $70.97 | +140.8% | $2.1B |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
LNG CHENIERE ENERGY INC | 8.09% | $42.98 | $269.03 | +526.0% | $3.8B |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
VSAT VIASAT INC | 7.89% | $70.34* | $70.38 | +0.1% | $966.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
QRVO QORVO INC | 7.71% | $67.34 | $114.48 | +70.0% | $1.3B |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
AGN ALLERGAN UNLTD CO | 7.22% | $206.35 | $177.10 | -14.2% | $876.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PXD PIONEER NATURAL RESOURCES CO | 6.62% | $172.13 | $262.50 | +52.5% | $1.1B |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
90130A200 TWENTY FIRST CENTY FOX INC | 5.86% | $32.91 | $47.78 | +45.2% | $650.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
AR ANTERO RESOURCES CORP | 4.96% | $21.59 | $33.39 | +54.7% | $887.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
19626G108 COLONY CAP INC NEW | 2.71% | $6.25 | $6.48 | +3.7% | $322M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
| 2.68% | — | — | — | $306.3M | |
T AT&T INC | 2.66% | $32.11 | $24.40 | -24.0% | $231.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CAH CARDINAL HEALTH INC | 2.18% | $67.25 | $222.50 | +230.9% | $1.1B |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
046513107 ATARA BIOTHERAPEUTICS INC | 2.01% | — | $1.48 | — | $9.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
MCK MCKESSON CORP | 1.90% | $152.69 | $853.81 | +459.2% | $1.4B |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
TBPH THERAVANCE BIOPHARMA INC | 1.85% | $30.35 | $16.23 | -46.5% | $151.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PCG P G & E CORP | 1.67% | $43.52 | $18.38 | -57.8% | $82.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
COR CENCORA INC | 1.40% | $89.04 | $300.28 | +237.3% | $562.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
VRTV VERITIV CORP | 1.33% | $43.60 | $168.90 | +287.4% | $645.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
896047503 TRIBUNE MEDIA CO | 1.00% | $38.27 | $46.22 | +20.8% | $138.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
KERX KERYX BIOPHARMACEUTICALS | 0.85% | $14.16 | $3.40 | -76.0% | $87.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
829226109 SINCLAIR BROADCAST GROUP INC | 0.72% | $32.15 | $17.16 | -46.6% | $44.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
00165C104 AMC ENTMT HLDGS INC | 0.70% | $14.83 | $4.40 | -70.3% | $22M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
NG NOVAGOLD RESOURCES INC | 0.52% | $2.73* | $6.50 | +138.4% | $87.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
GTYHU GTY TECHNOLOGY HOLDINGS INC/ | 0.40% | $10.50 | $10.10 | -3.8% | $44.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
| 0.26% | — | — | — | $30M | |
PRTK PARATEK PHARMACEUTICALS INC | 0.21% | $29.51 | $2.21 | -92.5% | $5.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
89374L104 TRANSLATE BIO INC | 0.21% | $12.65 | $41.19 | +225.6% | $79.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
78516C106 SABAN CAP ACQUISITION CORP | 0.21% | $10.00 | $10.13 | +1.3% | $23.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
TMQ TRILOGY METALS INC | 0.20% | $0.78 | $2.10 | +169.8% | $27.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SHPG SHIRE PLC-ADR | 0.15% | $168.80 | $174.04 | +3.1% | $17.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
STNLU SENTINEL ENERGY SERVICES INC | 0.14% | $9.97 | $10.28 | +3.1% | $16.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SCACW SABAN CAPITAL ACQ-CW21 | 0.01% | $0.95 | $0.60 | -36.8% | $698K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
Average cost is an estimate, not the investor's actual purchase price: every quarter the share count rose, the added shares are counted at that quarter-end's 13F price, and sales keep the average. Latest price is the most recent 13F quarter-end price (Sep 30, 2026), and value is shares × latest price. * Held since before Jun 30, 2013, when our collected history starts, so the average starts from that quarter's price.
Changes in shares
Change in shares held vs Mar 31, 2018, for the 20 largest positions that changed. Bars are capped at ±100%; the label shows the actual change.
Sold out this quarter
Held on Mar 31, 2018 and not reported for Q2 2018.
| Stock | Prior weight | Prior shares | Prior value | Change |
|---|---|---|---|---|
| TWX TIME WARNER INC | 7.39% | 8,100,000 | $766.1M | EXIT |
| 19625W104 COLONY NORTHSTAR INC | 2.69% | 49,687,370 | $279.2M | EXIT |
| PBF PBF ENERGY INC-CLASS A | 2.59% | 7,924,175 | $268.6M | EXIT |
| 16965P103 CHIPMOS TECHNOLOGIES INC | 0.14% | 933,658 | $14.8M | EXIT |
| 34986J105 FORWARD PHARMA A/S | 0.06% | 2,848,003 | $6.2M | EXIT |
| OREXQ OREXIGEN THERAPEUTICS INC | 0.00% | 2,226,839 | $465K | EXIT |
SEC filings for Q2 2018
- 13F-HR 0001567619-18-000616 · accepted Aug 13, 2018, 20:17 UTC